These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 34768768)
1. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes. Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768 [TBL] [Abstract][Full Text] [Related]
2. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology. Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560 [TBL] [Abstract][Full Text] [Related]
3. Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation. Pollmann S; Scharnetzki D; Manikowski D; Lenders M; Brand E Front Immunol; 2021; 12():789142. PubMed ID: 34917096 [TBL] [Abstract][Full Text] [Related]
4. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584 [TBL] [Abstract][Full Text] [Related]
5. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832 [TBL] [Abstract][Full Text] [Related]
6. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease. Scharnetzki D; Stappers F; Lenders M; Brand E Mol Genet Metab; 2020; 131(1-2):229-234. PubMed ID: 32888778 [TBL] [Abstract][Full Text] [Related]
7. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. Prabakaran T; Nielsen R; Larsen JV; Sørensen SS; Feldt-Rasmussen U; Saleem MA; Petersen CM; Verroust PJ; Christensen EI PLoS One; 2011; 6(9):e25065. PubMed ID: 21949853 [TBL] [Abstract][Full Text] [Related]
8. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984 [TBL] [Abstract][Full Text] [Related]
9. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451 [TBL] [Abstract][Full Text] [Related]
10. Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene. Gervas-Arruga J; Cebolla JJ; Irun P; Perez-Lopez J; Plaza L; Roche JC; Capablo JL; Rodriguez-Rey JC; Pocovi M; Giraldo P BMC Genet; 2015 Sep; 16():109. PubMed ID: 26334996 [TBL] [Abstract][Full Text] [Related]
11. Flow Cytometry-Based Assay to Detect Alpha Galactosidase Enzymatic Activity at the Cellular Level. Fekete N; Li LK; Kozma GT; Fekete G; Pállinger É; Kovács ÁF Cells; 2024 Apr; 13(8):. PubMed ID: 38667321 [TBL] [Abstract][Full Text] [Related]
12. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach. Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103 [TBL] [Abstract][Full Text] [Related]
14. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976 [TBL] [Abstract][Full Text] [Related]
15. Chaperone Therapy in Fabry Disease. Weidemann F; Jovanovic A; Herrmann K; Vardarli I Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813 [TBL] [Abstract][Full Text] [Related]
16. A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV. Maalouf K; Jia J; Rizk S; Brogden G; Keiser M; Das A; Naim HY J Inherit Metab Dis; 2010 Aug; 33(4):445-9. PubMed ID: 20495958 [TBL] [Abstract][Full Text] [Related]
17. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410 [TBL] [Abstract][Full Text] [Related]